

BIB

ProShares Ultra Nasdaq Biotechnology

Analyst Report

This ETF offers 2x daily long leverage to the broad-based NASDAQ Biotechnology Index, making it a powerful tool for investors with a bullish short-term outlook for biotechnology or pharmaceuticals companies. Investors should note that BIB's leverage resets on a daily basis, which results in compounding of returns when held for multiple periods. BIB can be a powerful tool for sophisticated investors, but should be avoided by those with a low risk tolerance or a buy-and-hold strategy.

ESG Themes and Scores

5.4/10	21.29%	13.75%
ESG Rate	Global Percentile	Peer Percentile

Performance Data

	BIB	ETF Database Category Average	Factset Segment Average
1 Month	14.87%	-5.60%	14.87%
3 Month	25.89%	19.60%	25.89%
YTD Return	18.03%	8.21%	18.03%
1 Year Return	105.95%	38.84%	105.95%
3 Year Return	21.58%	15.83%	21.58%
5 Year Return	0.22%	2.41%	0.22%

Top 5 Holdings

Symbol	Holding	% Assets
Other	U.S. Dollar	35.38%
IQMM	ProShares GENIUS Money Market ETF	6.61%
VRTX	Vertex Pharmaceuticals Incorporated	4.72%
AMGN	Amgen Inc.	4.64%
GILD	Gilead Sciences, Inc.	4.14%

Vitals

Issuer	Proshare Advisors LLC
Brand	ProShares
Structure	ETF
Expense Ratio	0.95%
Inception	Apr 07, 2010
Index Tracked	NASDAQ Biotechnology Index (200%)

ETF Database Themes

Category	Leveraged Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	Growth
Region (General)	North America
Region (Specific)	U.S.

FactSet Classifications

Segment	Leveraged Equity: U.S. Pharma, Biotech & Life Sciences
Category	Sector
Focus	Health Care
Niche	Pharma, Biotech & Life Sciences
Strategy	Exchange-specific
Weighting	Market Cap

